As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer’s disease in older adults.
2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) ...
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Unhappily, oxybutynin hydrochloride, tolterodine tartrate and solifenacin succinate – the three linked to dementia – are considered the most effective drugs for treating overactive bladder.
The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS ...
A new pill that ‘slows down Alzheimer's ' is being considered for use in the NHS. Developed by a small British firm in ...
The drug was developed from methylene blue, a medicine previously used to treat malaria. Professor Alistair Burns, former NHS clinical director for dementia ... "After no new therapies for ...